HC Wainwright Weighs in on Mural Oncology Q1 Earnings

Mural Oncology plc (NASDAQ:MURA) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Mural Oncology in a note issued to investors on Wednesday, March 26th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of ($0.81) per share for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Mural Oncology’s current full-year earnings is ($7.54) per share. HC Wainwright also issued estimates for Mural Oncology’s Q2 2026 earnings at ($0.86) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.77) EPS and FY2026 earnings at ($3.32) EPS.

MURA has been the subject of a number of other reports. Jones Trading restated a “hold” rating on shares of Mural Oncology in a report on Tuesday. Raymond James downgraded shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 target price for the company. in a research report on Tuesday. Finally, Morgan Stanley lowered shares of Mural Oncology from an “overweight” rating to an “equal weight” rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Mural Oncology Price Performance

NASDAQ MURA opened at $1.18 on Friday. The company has a market cap of $20.33 million, a P/E ratio of -0.13 and a beta of 3.66. Mural Oncology has a 12 month low of $1.12 and a 12 month high of $5.02. The company has a 50-day moving average of $3.72 and a 200-day moving average of $3.57.

Mural Oncology (NASDAQ:MURA) last released its earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same quarter in the previous year, the business posted ($3.57) earnings per share.

Institutional Investors Weigh In On Mural Oncology

A number of large investors have recently modified their holdings of MURA. Commerce Bank purchased a new position in Mural Oncology in the 3rd quarter worth approximately $39,000. FMR LLC lifted its position in shares of Mural Oncology by 124.7% during the third quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after purchasing an additional 11,423 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Mural Oncology in the fourth quarter valued at $68,000. Two Sigma Advisers LP acquired a new stake in Mural Oncology during the 4th quarter valued at $84,000. Finally, Bridgeway Capital Management LLC purchased a new stake in Mural Oncology during the 4th quarter worth $94,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.